CNSP - CNS Pharmaceuticals, Inc.

1.03
-0.090   -8.738%

Share volume: 242,103
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.12
-0.09
-0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
23%
Profitability 0%
Dept financing 25%
Liquidity 43%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.88%
1 Month
-56.92%
3 Months
865.52%
6 Months
779.81%
1 Year
400.00%
2 Year
-97.01%
Key data
Stock price
$1.03
P/E Ratio 
0.00
DAY RANGE
$1.00 - $1.18
EPS 
-$8.81
52 WEEK RANGE
$0.07 - $16.00
52 WEEK CHANGE
$389.08
MARKET CAP 
4.195 M
YIELD 
N/A
SHARES OUTSTANDING 
32.146 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-21-2025
NEXT EARNINGS DATE
04-15-2025
BETA 
2.15
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$248,660
AVERAGE 30 VOLUME 
$336,234
Company detail
CEO: John M. Climaco
Region: US
Website: cnspharma.com
Employees: 5
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

CNS Pharmaceuticals, Inc. engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials.

Recent news
loading